Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited Fundamental Analysis
Alembic Pharmaceuticals Limited (APLLTD.NS) shows moderate financial fundamentals with a PE ratio of 23.12, profit margin of 8.66%, and ROE of 12.22%. The company generates $72.7B in annual revenue with moderate year-over-year growth of 7.12%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 51.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze APLLTD.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakAPLLTD.NS struggles to generate sufficient returns from assets.
Valuation Score
ExcellentAPLLTD.NS trades at attractive valuation levels.
Growth Score
ModerateAPLLTD.NS shows steady but slowing expansion.
Financial Health Score
ExcellentAPLLTD.NS maintains a strong and stable balance sheet.
Profitability Score
WeakAPLLTD.NS struggles to sustain strong margins.
Key Financial Metrics
Is APLLTD.NS Expensive or Cheap?
P/E Ratio
APLLTD.NS trades at 23.12 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, APLLTD.NS's PEG of -29.82 indicates potential undervaluation.
Price to Book
The market values Alembic Pharmaceuticals Limited at 2.73 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.68 times EBITDA. This signals the market has high growth expectations.
How Well Does APLLTD.NS Make Money?
Net Profit Margin
For every $100 in sales, Alembic Pharmaceuticals Limited keeps $8.66 as profit after all expenses.
Operating Margin
Core operations generate 21.53 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.22 in profit for every $100 of shareholder equity.
ROA
Alembic Pharmaceuticals Limited generates $7.49 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Alembic Pharmaceuticals Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Alembic Pharmaceuticals Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
APLLTD.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
23.12
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-29.82
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.73
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.001
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.28
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.59
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.28
vs 25 benchmark
How APLLTD.NS Stacks Against Its Sector Peers
| Metric | APLLTD.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 23.12 | 29.45 | Better (Cheaper) |
| ROE | 12.22% | 779.00% | Weak |
| Net Margin | 8.66% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.28 | 0.26 | Neutral |
| Current Ratio | 1.59 | 4.65 | Neutral |
| ROA | 7.49% | -19344.00% (disorted) | Weak |
APLLTD.NS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alembic Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
38.93%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-32.49%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-81.22%
Industry Style: Defensive, Growth, Innovation
Declining